Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript

Core Insights - The call discusses data presented at the Theranostics World Conference in South Africa regarding MP0712, a DLL3 targeting radiotherapeutic [2] - The data includes clinical imaging and dosimetry results from a named patient access program under South Africa's Section 21 of the Medicines and Related Substances Act [2] Company Information - The presentation is led by Seth Lewis, the Head of Investor Relations and Strategy, indicating a structured approach to investor communication [2] - The clinical study was supervised by Dr. Mike Sathekge, a prominent figure in Nuclear Medicine at the University of Pretoria and Steve Biko Academic Hospital [3]